TABLE 2.
Specific reactivity of virally induced anti-MART-1 cytotoxic T lymphocytes (CTL) against various HLA-A*0201 compatible MART-1-derived peptides and naturally processed MART-1 epitopes on tumor cells
| T2 + MART-1 peptide
|
||||||||
|---|---|---|---|---|---|---|---|---|
| Effector | 27–35 | 31–39 | 32–40 | 35–43 | 56–64 | T2 + G9-209-2M | 624.38-Mel | 624.28-Mel |
| CTL-1 | 1,724 | 0 | 0 | 0 | 54 | 34 | 815 | 0 |
| CTL-2 | 666 | 184 | 204 | 195 | 160 | 156 | 209 | 60 |
| CTL-3 | 683 | 64 | 49 | 56 | 124 | 93 | 137 | 35 |
| CTL-4 | 438 | 91 | 99 | 114 | 7 | 0 | 58 | 0 |
| CTL-5 | 3,924 | 392 | 396 | 424 | 404 | 340 | 1,416 | 147 |
| CTL-6 | 844 | 392 | 356 | 344 | 348 | 376 | 44 | 0 |
| A42 anti-MART-1 27-35 clone | >4,000 | 0 | 54 | 0 | 0 | 0 | 2,559 | 13 |
| 1235 TIL | >4,000 | 5 | 155 | 0 | 53 | 12 | 3,704 | 30 |
| Anti-G9 209-2M CTL | 0 | 0 | 0 | 0 | 0 | >4,000 | 1,154 | 0 |
CTL 1–6 were raised by stimulation with dendritic cells (DC) infected with rV-MART-1 and restimulated after 7 days with DC infected with rF-MART-1. Interferon-γ release (pg/5 × 105 CD8− cells/24 h) was analyzed against T2 cells pulsed with peptide (2 μg/ml) or against the HLA-A*0201+/MART-1 + 624.38 MEL or the HLA-A*0201 –/MART-1 + 624.28 MEL melanoma clones (37). As effector controls, anti-MART-127-35 A42 CTL clone and 1235 tumor-infiltrating lymphocytes and anti-G9-209-2M CTL were used.